Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rui Avelar Insider Profile
4 Followers
Rui Avelar, Chief Medical Officer & Head of Research and Development at Evolus, holds 372.29K shares in Evolus (Ticker: EOLS). Most recently, Rui Avelar Sold $27,603 shares of Evolus on Mar 21, 2024 for an estimated value of 384.23K.
Rui Avelar Evolus (EOLS)Chief Medical Officer & Head of Research and Development
Evolus (EOLS)
Chief Medical Officer & Head of Research and Development
Ranked #74,079 out of 98,743 Corporate Insiders
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
-31.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
Chief Medical Officer & Head of Research and Development
Roles that Rui Avelar holds in companies
Most Profitable Insider Trade
The most profitable trade made by Rui Avelar
Rui Avelar's Trading History
List of latest transactions for each holding click on a transaction to see Rui Avelar's performance on stock
You May Also Like
Rui Avelar insider profile FAQ
What is the percentage of profitable transactions made by Rui Avelar?
The percentage of profitable transactions made by Rui Avelar is 50%.
What is the average return per transaction made by Rui Avelar?
The average return per transaction made by Rui Avelar is -31.80%.
What stocks does Rui Avelar hold?
Rui Avelar holds: EOLS stocks.
What was Rui Avelar’s latest transaction?
Rui Avelar latest transaction was an Informative Sell of $384.23K.
What was Rui Avelar's most profitable transaction?
Rui Avelar’s most profitable transaction was an Informative Sell of EOLS stock on March 21, 2024. The return on the trade was 3.50%.
What is Rui Avelar's role in Evolus?
Rui Avelar's role in Evolus is Chief Medical Officer & Head of Research and Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.